Monday, September 5, 2011
I have been invited to participate in a meeting later in September where the FDA, congressional staffers, the pharmaceutical industry large and small, clinicians and finally, the press will gather. The purpose of the meeting is to expose for congressional staffers the special nature of antibiotics and the challenges currently faced by society in bringing needed new antibiotics from the research laboratory to patients and clinicians. I need to explain that I have been invited not as a participant from industry, not as a clinician or scientist, but as a member of the press. I don’t know if I should be grateful to have been invited at all (I am!) or if I should be insulted. What do you think?
The draft agenda I have seen suggests that there will first be a discussion of antibiotics and areas of current urgent medical needs for new products. This will be followed by a discussion of the regulatory challenges for antibiotics followed by a discussion of the economic challenges for companies and academics wanting to bring new products to market. Of course, there is nothing in this meeting that has not been discussed previously ad nauseum. There have been multiple reviews from IDSA and others summarizing the dire threat of rising antibiotic resistance both in our hospitals and our communities. The clinical needs are clear and are becoming more urgent with time, especially for treatment of Gram-negative infections.
The regulatory situation, especially in the US, has been the subject of countless FDA advisory committee meetings, IDSA-FDA workshops, and has been discussed publicly in a variety of other forums. There have been many appearances on Capitol Hill by infectious diseases clinicians, the IDSA and industry discussing the medical need, regulatory environment and economics of antibiotic development. So, while I welcome the opportunity for another shot on goal with Congress, I don’t understand what it is that they don’t get. Are they not listening? Do they not care? If it’s the latter, let’s not waste more time. If it’s the former, what makes us think they will listen now – especially in the current political and economic climate?
I recently had a discussion with a colleague on incentives in regard to this upcoming meeting. I have been contemplating once again the various economic incentives that could be used to encourage industry to get back in the antibiotics game. But you know what? Effective incentives for industry will never be passed in the current political and economic environment. Lets face it. But, even though I find that disappointing, I disagree with my colleagues who are prioritizing incentives over regulatory reform. As I have stated on multiple occasions, without a clear regulatory path for antibiotic development in the US, no amount of money will suffice to attract industry back into the business.
As I see the ongoing evolution of the state of antibiotic research and development within industry, we have probably reached bottom. The number of large pharmaceutical companies exiting the area will now be balanced by those getting back in to one extent or the other. I see the imminent departure of Novartis balanced by the arrival of Sanofi-Aventis and the toe-dipping exercise of Bayer with Trius.
We should learn from the companies who are getting back into the business, Sanofi-Aventis and Bayer. I believe that both, but most certainly Bayer, are targeting Asia. Why? There is a clear regulatory path forward and a growing market – especially for antibiotics. The clear regulatory path, so far, is coming from Europe where one can leverage a European approval to win approval in most emerging economy countries. The US has a clear regulatory path for skin infections – period. The pathway for respiratory infections no longer exists. The FDA has promised new guidelines for intraabdominal infections and for urinary tract infection. This does nothing but increase fear and uncertainty in industry given what has already happened with respiratory infections. So the US market is being wiped off the map by our lack of a clear and feasible regulatory path for key antibiotic indications. Companies see this clearly but they also see the rising market opportunities in the merging economies especially in Asia-Pacific (see figure - Antibiotic sales in dollars last 5 years 2006-10). This leaves us n a situation where needed new antibiotics will be developed and will be available for patients and physicians in China and India but not for Americans here in the US.
So – here’s my suggestion for Congress. It won’t cost taxpayers a dime. Ask the FDA in public hearings why we do not have feasible regulatory paths for the development of needed new antibiotics and why India is a more attractive places to develop and sell antibiotics than the US. In my view, at this point in time, this is the only practical starting point in the real world. Of course my caveat is that Congress doesn’t really know what it’s doing either . . .
Now – my conundrum. I want to participate in the meeting I mentioned earlier. But as a member of the press, I probably can’t get up and make statements. I will actually have to ask questions to make my points. I’m not sure I know how to do that. So – any suggestions are much appreciated.